Brexpiprazole’s indication for the treatment of schizophrenia in adults is extended to include adolescents aged 13 years and older1 Approval follows a positive Committee for Medicinal Products for Human Use (CHMP) opinion from the European Medicines Agency in January 20252 Treatment with…